Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Bendorf

27 clinical trials in Bendorf, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Bendorf at a glance
27
clinical trials
  • Paediatric trials0
  • Research sites0
Type of trial
Recruitment status
Quick filters

27 trials in Bendorf

Open in trial search

Study of PF-07275315 versus placebo for efficacy and safety in adults with moderate-to-severe chronic obstructive pulmonary disease (COPD)

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Sponsor:Pfizer Inc.

Asthma

Recruiting

Study to evaluate the long-term safety and effectiveness of lunsekimig in adults with moderate to severe asthma

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Asthma

Recruiting

A Study of Brenipatide Compared to Placebo for Adults with Uncontrolled Moderate to Severe Asthma

Investigational
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:LY3537031
  • Sponsor:Eli Lilly & Co.

Study of AZD6793 tablets to reduce flare-ups in adults with moderate to very severe chronic obstructive pulmonary disease (COPD)

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Sponsor:AstraZeneca AB

Asthma

Recruiting

Efficacy and Safety of Depemokimab for Early Intervention in Adults and Adolescents with Type 2 Asthma at Risk of Exacerbations

Registered drug
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Depemokimab
  • Sponsor:Glaxosmithkline Research & Development Limited

Efficacy and safety of lunsekimig in adults with inadequately controlled eosinophilic COPD: a randomized, double‑blind, placebo‑controlled trial

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Lunsekimig
  • Sponsor:Sanofi-Aventis Recherche & Developpement

A study to evaluate the efficacy and safety of depemokimab and salbutamol sulfate in patients with chronic obstructive pulmonary disease and type 2 inflammation.

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Depemokimab
  • Sponsor:Glaxosmithkline Research & Development Limited

Bronchiectasis

Recruiting

A study testing GSK3862995B compared to placebo for safety and effectiveness in adults aged 18 to 85 years with bronchiectasis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:GSK3862995B
  • Sponsor:GSK PLC

A Study of Depemokimab Compared to Placebo in Adults with Chronic Obstructive Pulmonary Disease and Type 2 Inflammation

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Depemokimab
  • Sponsor:Glaxosmithkline Research & Development Limited

Asthma

Recruiting

Testing WIN378 Safety and Effects in Adults with Moderate or Severe Asthma

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Human IgG1 monoclonal antibody against TSLP
  • Sponsor:Windward Bio AG

Study of Tezepelumab Compared to Placebo in Adults with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Tezepelumab
  • Sponsor:AstraZeneca AB

Bronchiectasis

Not yet recruiting

A Study of SAR445399 in Adults Aged 18‑80 with Non‑cystic Fibrosis Bronchiectasis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:SAR445399
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Other cities in Germany

The busiest research cities in the country

All 518 cities in Germany

Clinical research in Bendorf

What the registry says about research in the country

01 Respiratory Disease Research

Groundbreaking studies focusing on chronic obstructive pulmonary disease (COPD) and its treatment approaches. Research initiatives are evaluating novel therapies to reduce exacerbations and improve patient outcomes.

  • COPD Management
  • Exacerbation Prevention
  • Long-term Safety Studies

Multiple trials are investigating innovative treatments for moderate to very severe COPD patients.

02 Asthma Studies

Comprehensive research into severe and moderate asthma treatments, with particular attention to patients with inadequately controlled symptoms. Studies are exploring new biological therapies and combination treatments.

  • Eosinophilic Asthma
  • Therapeutic Antibodies
  • Inhaler Medications

Clinical investigations focus on improving lung function and reducing asthma exacerbations.

03 Bronchiectasis Research

Innovative studies examining treatments for non-cystic fibrosis bronchiectasis, evaluating new therapeutic approaches to manage pulmonary exacerbations and improve patient quality of life.

  • Anti-IL-33 Treatments
  • Exacerbation Prevention
  • Novel Therapeutics

Research aims to develop targeted treatments for bronchiectasis patients.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.